Role of novel kidney injury biomarkers in perioperative acute kidney injury

Chirag R. Parikh, William R. Zhang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.

Original languageEnglish (US)
Title of host publicationPerioperative Kidney Injury
Subtitle of host publicationPrinciples of Risk Assessment, Diagnosis and Treatment
PublisherSpringer New York
Pages25-36
Number of pages12
ISBN (Electronic)9781493912735
ISBN (Print)9781493912728
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Role of novel kidney injury biomarkers in perioperative acute kidney injury'. Together they form a unique fingerprint.

Cite this